Retinal vascular occlusion and deficiencies in the protein C pathway

被引:69
作者
Greiner, K
Hafner, C
Dick, B
Peetz, D
Prellwitz, W
Pfeiffer, N
机构
[1] Univ Mainz, Dept Ophthalmol, D-6500 Mainz, Germany
[2] Univ Mainz, Dept Lab Med, D-6500 Mainz, Germany
关键词
D O I
10.1016/S0002-9394(99)00074-4
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
PURPOSE: To report abnormalities in the protein C pathway and other vascular occlusion risk factors in patients with retinal vascular occlusion, METHODS: In a study, we investigated 76 consecutive patients who had in-patient evaluation of venous or arterial retinal vascular occlusion. All patients underwent comprehensive tests for coagulation disorders including determinations of protein C, protein S, lupus anticoagulants, and resistance to activated protein C and were screened for vascular disease risk factors. Resistance to activated protein C was confirmed by a polymerase chain reaction method to detect the specific factor V R506Q mutation. For comparative purposes, we also screened 209 consecutive inpatients with deep vein thrombosis from the same geographic region for resistance to activated protein C as well as protein C and protein S deficiencies. RESULTS: Ten (29%) of 35 patients with central retinal vein occlusion (CRVO) had factor V R506Q mutation. The factor V R506Q mutation was detected in four (19%) of 21 patients with branch retinal vein occlusion. The higher frequency in factor V R506Q mutation compared with the expected 9% mutation prevalence in a white population was highly significant for the central retinal vein occlusion group but not for the branch retinal vein occlusion group. In all patients with resistance to activated protein C, the factor V R506Q mutation was detected; 16 were heterozygous, one homozygous, No cases of lupus anticoagulants, protein C, or protein S deficiencies were detected. Forty (19%) of 209 patients with deep vein thrombosis were carriers of the factor V R506Q mutation. CONCLUSIONS: The prevalence of the factor V R506Q mutation is similar in patients with central retinal vein occlusion and patients with deep vein thrombosis and represents a relevant risk factor. Screening for this mutation is therefore recommended in all patients with central retinal vein occlusion. (Am J Ophthalmol 1999;128:69-74; (C) 1999 by Elsevier Science Inc. All rights reserved.)
引用
收藏
页码:69 / 74
页数:6
相关论文
共 41 条
[31]   ISCHEMIC STROKE IN YOUNG-PATIENTS WITH ACTIVATED PROTEIN-C RESISTANCE - A REPORT OF 3 CASES BELONGING TO 3 DIFFERENT KINDREDS [J].
SIMIONI, P ;
DERONDE, H ;
PRANDONI, P ;
SALADINI, M ;
BERTINA, RM ;
GIROLAMI, A .
STROKE, 1995, 26 (05) :885-890
[32]   RESISTANCE TO ACTIVATED PROTEIN-C AS A BASIS FOR VENOUS THROMBOSIS [J].
SVENSSON, PJ ;
DAHLBACK, B .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (08) :517-522
[33]   Retinal arterial occlusion in a child with factor V Leiden and thermolabile methylene tetrahydrofolate reductase mutations [J].
Talmon, T ;
Scharf, J ;
Mayer, E ;
Lanir, N ;
Miller, B ;
Brenner, B .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1997, 124 (05) :689-691
[34]  
vanderMeer FJM, 1997, THROMB HAEMOSTASIS, V78, P631
[35]   THE ROLE OF ABNORMALITIES IN THE ANTICOAGULANT AND FIBRINOLYTIC SYSTEMS IN RETINAL VASCULAR OCCLUSIONS [J].
VINE, AK ;
SAMAMA, MM .
SURVEY OF OPHTHALMOLOGY, 1993, 37 (04) :283-292
[36]   Screening for resistance to activated protein C and the mutant gene for factor V:Q506 in patients with central retinal vein occlusion [J].
Vine, AK ;
Samama, MM .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1997, 124 (05) :673-676
[37]   Blood viscosity, coagulation, and activated protein C resistance in central retinal vein occlusion: A population controlled study [J].
Williamson, TH ;
Rumley, A ;
Lowe, GDO .
BRITISH JOURNAL OF OPHTHALMOLOGY, 1996, 80 (03) :203-208
[38]  
YATES F, 1987, BIOMETRICS, V43, P471
[39]  
ZEGARRA H, 1979, OPHTHALMOLOGY, V86, P1931
[40]   RESISTANCE TO ACTIVATED PROTEIN-C AS AN ADDITIONAL GENETIC RISK FACTOR IN HEREDITARY-DEFICIENCY OF PROTEIN-S [J].
ZOLLER, B ;
BERNTSDOTTER, A ;
DE FRUTOS, PG ;
DAHLBACK, B .
BLOOD, 1995, 85 (12) :3518-3523